Bcma car-t cells with enhanced activities
AssigneeAllogene Therapeutics, Inc.
InventorsRegina Junhui LIN, Siler PANOWSKI, Cesar Adolfo SOMMER, Thomas John VAN BLARCOM, Barbra Johnson SASU, Arun BALAKUMARAN
Life of this patent
Estimating the term…
Loading patent…
AssigneeAllogene Therapeutics, Inc.
InventorsRegina Junhui LIN, Siler PANOWSKI, Cesar Adolfo SOMMER, Thomas John VAN BLARCOM, Barbra Johnson SASU, Arun BALAKUMARAN
Estimating the term…
Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR). Also provided herein are engineered immune cells that comprise one or more nucleic acids e.g. a bicistronic vector such as a viral vector that encode the CACCRs and BCMA CARs and engineered immune cells e.g. engineered autologous or allogeneic T cells that express both CACCRs and BCMA CARs from the nucleic acids. When present on chimeric antigen receptor (CAR)-bearing engineered immune cells, the CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Further provided herein are methods of making and using the engineered immune cells described herein, such as methods of treating a disease or condition by administering at least one appropriate dose of the cells to a patient suffering from the condition.
An engineered immune cell comprising an anti-BCMA chimeric antigen receptor (CAR) and a constitutively active chimeric cytokine receptor (CACCR), wherein the CACCR comprises two monomers, each monomer comprising:
An engineered immune cell that comprises one or more polynucleotides that encode a BCMA CAR polypeptide that comprises the amino acid sequence of SEQ ID NO:
(canceled)
At least one isolated polynucleotide encoding a BCMA CAR that comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.